BIOPHYTIS
Biophytis is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Their goal is to become a leader in the emerging field of aging science by delivering life-changing therapies to the growing number of patients in need that have limited or no treatment options. To accomplish this goal, they have assembled an experienced and skilled group of industry professionals, scientists, clinicians and key opinion leaders from leading industry and academic institutions from around the world.
BIOPHYTIS
Industry:
Biotechnology Nutraceutical Pharmaceutical
Founded:
2006-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.biophytis.com
Total Employee:
11+
Status:
Active
Contact:
+33 1 44 27 23 00
Total Funding:
34.34 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Current Employees Featured
Rob van Maanen Chief Medical Officer @ Biophytis
Chief Medical Officer
2021-09-01
Philippe Rousseau Chief Financial Officer @ Biophytis
Chief Financial Officer
2022-04-01
Rene Lafont Chief Scientific Officer @ Biophytis
Chief Scientific Officer
Stanislas Veillet President & CEO @ Biophytis
President & CEO
2006-04-01
Samuel Agus CMO @ Biophytis
CMO
2018-07-01
Dimitri Batsis Administrator @ Biophytis
Administrator
2018-01-01
Founder
Stock Details
Investors List
Kreos Capital
Kreos Capital investment in Post-IPO Debt - Biophytis
Atlas Capital Markets
Atlas Capital Markets investment in Post-IPO Equity - Biophytis
Bpifrance
Bpifrance investment in Post-IPO Debt - Biophytis
Bpifrance
Bpifrance investment in Grant - Biophytis
Metabrain Research SAS
Metabrain Research SAS investment in Series B - Biophytis
CM-CIC Capital Prive
CM-CIC Capital Prive investment in Series B - Biophytis
Seventure Partners
Seventure Partners investment in Series B - Biophytis
AGORANOV
AGORANOV investment in Venture Round - Biophytis
Key Employee Changes
| Date | New article |
|---|---|
| 2022-04-05 | Biophytis appoints Philippe Rousseau as Chief Financial Officer |
Official Site Inspections
http://www.biophytis.com
- Host name: 151-236-54-229.static.as29550.net
- IP address: 151.236.54.229
- Location: United Kingdom
- Latitude: 51.4964
- Longitude: -0.1224
- Timezone: Europe/London
More informations about "Biophytis"
Corporate – Biophytis
Biophytis is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and …See details»
Biophytis
Biophytis is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and …See details»
Biophytis (EPA:ALBPS) Company Profile & Description - Stock …
Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. The company was incorporated in 2006 and is headquartered in …See details»
Biophytis - Crunchbase Company Profile & Funding
Biophytis announced its 2023 financial results and provided an update on its business activities. The company also launched a trial targeting muscle loss in …See details»
Biophytis Company Profile - Office Locations, Competitors, …
Oct 29, 2024 Biophytis (formerly known as Institut Biophytis) is a biotechnology company focused on the development of drug candidates for the treatment of age-related diseases. It …See details»
Biophytis Announces New Non-Clinical Data Further Supporting …
19 hours ago Biophytis is pioneering research to address this critical unmet medical need. We are eager to advance the development of BIO101 in combination with GLP-1 within our Phase …See details»
Corporate Presentation - Biophytis
Download the latest corporate presentation of Biophytis and get the latest information on ongoing studies.See details»
Biophytis - Org Chart, Teams, Culture & Jobs - The Org
View Biophytis' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Biophytis - SPEEDA Edge
Biophytis is a clinical-stage biotech company specialized in developing therapeutics to slow the degenerative processes associated with aging and improve functional outcomes for patients …See details»
Biophytis Unveils Its Outlook Strategies for 2025 - Yahoo Finance
Feb 11, 2025 Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - February 11, 2025) - Biophytis SA (FP: ALBPS), ("Biophytis" or the "Company"), a clinical-stage …See details»
Biophytis Announces New Non-Clinical Data Further Supporting
11 hours ago About BIOPHYTIS. Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. BIO101 (20 …See details»
Biophytis - Contacts, Employees, Board Members, Advisors & Alumni
Biophytis is a research company that focuses on the fields of metabolic and age-related diseases. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. Log In. …See details»
Biophytis - Updates, News, Events, Signals & Triggers - Crunchbase
Biophytis is a research company that focuses on the fields of metabolic and age-related diseases.See details»
Biophytis (LON:0D1W) Company Profile & Description - Stock …
Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. The company was incorporated in 2006 and is headquartered in …See details»
Biophytis S.A.: Governance, Directors and Executives
89d8aa04152.qrP7UiQdf_C7uE6d2uHZaeZ6jOiqRoz-Q3lYSCXQX5w.3fKvPWgwD76J_Cnzr5KUGssKvKOeGdvGex8dG1zkCMT5550Xc00up8vKCw …See details»
Biophytis Revolutionizes Sarcopenia - Nasdaq
Mar 17, 2025 Biophytis is the most advanced company in this indication with BIO101 *** About BIOPHYTIS. Biophytis SA is a clinical-stage biotechnology company focused on developing …See details»
6XB3.DE | Biophytis Company Profile & Executives - WSJ
Company profile for Biophytis including key executives, insider trading, ownership, revenue and average growth rates. View detailed 6XB3.DE description & address.See details»
Biophytis SA
Stanislas Veillet, CEO of Biophytis, stated: "The Covid pandemic is far from over: according to the World Health Organization, 134,797 new cases of Covid-19 and 1,691 deaths have been …See details»
Biophytis
Biophytis révolutionne la sarcopénie Publication des résultats de Phase II (étude SARA-INT) Confirmation du passage à la Phase 3 pour BIO101 Biophytis est heureuse d’annoncer une …See details»
Biophytis announces ratio change under its American Depositary …
Mar 17, 2023 Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program Paris (France), Cambridge (Massachusetts, U.S.), March 17th, 2023, 08 am CET – …See details»